Section Arrow
MESO.NASDAQ
- Mesoblast Limited
Quotes are at least 15-min delayed:2026/06/03 16:41 EDT
After Hours
Last
 14.23
-0.29 (-2.00%)
Bid
12.5
Ask
15.05
High 14.52 
Low 14.23 
Volume 13 
Regular Hours (Closed)
Last
 14.52
0 (0.00%)
Day High 
14.55 
Prev. Close
14.52 
1-M High
16.06 
Volume 
107.96K 
Bid
12.5
Ask
15.05
Day Low
14.27 
Open
14.4 
1-M Low
14.3 
Market Cap 
1.88B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.84 
20-SMA 14.89 
50-SMA 15.08 
52-W High 21.5 
52-W Low 9.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/-0.08
Enterprise Value
1.95B
Balance Sheet
Book Value Per Share
4.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.46M
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0949-0.0149-13.57%-- 
After Hours 0.0939 -0.001 -1.05%
VRAXVirax Biolabs Group Limited0.2401+0.0238+11.00%-- 
After Hours 0.2105 -0.0296 -12.33%
RXRXRecursion Pharmaceuticals3.47-0.14-3.88%-- 
After Hours 3.46 -0.01 -0.29%
CLDICalidi Biotherapeutics0.1656-0.0145-8.05%-- 
After Hours 0.1699 +0.0043 +2.60%
GOSSGossamer Bio0.1883-0.0119-5.94%-- 
After Hours 0.1889 +0.0006 +0.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.